Persistence with Migraine Prophylactic Treatment and Acute Migraine Medication Utilization in the Managed Care Setting

Clinical Therapeutics

Volumn 30, Issue 12, 2008, Pages 2452-2460

  Yaldo, Avin Z ^a   Wertz, Debra A ^b   Rupnow, Marcia F T ^a   Quimbo, Ralph M ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b HEALTHCORE INC   (United States)

Author keywords

headache; migraine prophylaxis; resource use; topiramate; triptans

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; ERGOTAMINE DERIVATIVE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROPRANOLOL; TIMOLOL; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROATE SEMISODIUM;

ACUTE DISEASE; ADULT; ARTICLE; BILLING AND CLAIMS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MIGRAINE; PATIENT COMPLIANCE; PHARMACY; PRESCRIPTION; PROPHYLAXIS;

ADULT; AGE FACTORS; AMITRIPTYLINE; COHORT STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; FRUCTOSE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; MIDDLE AGED; MIGRAINE DISORDERS; PROPORTIONAL HAZARDS MODELS; PROPRANOLOL; RETROSPECTIVE STUDIES; SEX FACTORS; TIME FACTORS; TIMOLOL; VALPROIC ACID;

EID: 58249128373     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.010     Document Type: Article

References (26)

1. Lipton R.B., Stewart W.F., Diamond S., et al. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 41 (2001) 646-657
2. Etemad L.R., Yang W., Globe D., et al. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis. J Manag Care Pharm 11 (2005) 137-144
3. Hawkins K., et al. Direct cost burden of migraine among members of US employers. Presented at: 48th Annual Meeting of the American Headache Society; Los Angeles, Calif; June 22-25 (2006)
4. Hu X.H., Markson L.E., Lipton R.B., et al. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 159 (1999) 813-818
5. Silberstein S.D. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology [published correction appears in Neurology. 2000;56:142]. Neurology 55 (2000) 754-762
6. Lipton R.B., Bigal M.E., Diamond M., et al., for the AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68 (2007) 343-349
7. Rahimtoola H., Buurma H., Tijssen C.C., et al. Migraine prophylactic medication usage patterns in The Netherlands. Cephalalgia 23 (2003) 293-301
8. Sabatâe E., and for the World Health Organization. Adherence to long-term therapies: Evidence for action (2003), World Health Organization, Geneva, Switzerland
9. Hedenrud T., Jonsson P., and Linde M. Beliefs about medicines and adherence among Swedish migraineurs. Ann Pharmacother 42 (2008) 39-45
10. Ramadan N.M., Silberstein S.D., Freitag F.G., et al. Evidencebased guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of migraine (Accessed June 13, 2008). http://www.aan.com/professionals/practice/pdfs/gl0090.pdf
11. Mantel N. Why stepdown procedures in variable selection. Technometrics 12 (1970) 621-625
12. Modeling survival data: Extending the Cox model. In: Therneau T.M., and Grambsch P.M. (Eds). Statistics for Biology and Health. 1st ed. (2000), Springer Verlag, New York, NY 127-142
13. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.]. Clin Epidemiol 45 (1992) 613-619
14. Elavil (amitriptyline HCI) [package insert] [CDER Web site]. (November 18, 2008). http://www.fda.gov/cder/foi/label/2001/I2704s451bl.pdf
15. Inderal (propranolol HCI) [package insert] [Medwatch Web site] (November 18, 2008). http://www.fda.gov/medwatch/SAFETY/2007/Jan_PI/InderalLA_Pl.pdf
16. Timolol (timolol maleate) [package insert] [drugs.com Web site] (Accessed November 18, 2008). http://www.drugs.com/pro/timolol.html
17. Depakote (divalproex sodium) [package insert] (Accessed November 18, 2008). http://www.rxabbott.com/pdf/depakote.pdf
18. Topamax (topiramate) [prescribing information] [Topamax Web site] (November 18, 2008). http://www.topamax.com/Topamax/assets/Topamax.pdf
19. Stark R.J., Valenti L., and Miller G.C. Management of migraine in Australian general practice. Med J Aust 187 (2007) 142-146
20. Silberstein S.D., Feliu A.L., Rupnow M.F., et al. Topiramate in migraine prophylaxis: Long-term impact on resource utilization and cost. Headache 47 (2007) 500-510
21. Feliu A.L., Rupnow M.F., Blount A., et al. Resource use associated with topiramate in migraine prophylaxis. Am j Health Syst Pharm 64 (2007) 1483-1491
22. Silberstein S.D., Neto W., Schmitt J., Jacobs D., and for the MIGR-001 Study Group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol 61 (2004) 490-495
23. McCombs J.S., Nichol M.B., Newman C.M., and Sclar D.A. The costs of interrupting anti hypertensive drug therapy in a Medicaid population. Med Care 32 (1994) 214-226
24. Brandes J.L., Saper J.R., Diamond M., et al., for the MIGR-002 Study Group. Topiramate for migraine prevention: A randomized controlled trial. JAMA 291 (2004) 965-973
25. Pizzi L., Gagne J.J., Lofland J.H., et al. Effect of topiramate migraine prophylaxis on work-place productivity: Results from two US randomized, double-blind, placebo-controlled, multicentertrials. Headache 46 (2006) 852
26. Diamond M., Dahlbf C., Papadopoulos G., et al. Topiramate improves health-related quality of life when used to prevent migraine. Headache 45 (2005) 1023-1030